ACTR-70. INCREASING SURVIVAL IN BIOPSY-ONLY GBM PATIENTS

ABSTRACT: Abstract It is generally expected that survival from GBM is correlated to the extent of resection. That is, patients having only a biopsy don’t live as long as those having partial or complete resections. Fifteen years ago, 2-year survival of biopsy-only patients was 5%. In 2005, Stupp et al. added temozolomide (TM Z) to radiation therapy and also established a follow-up TMZ chemotherapy regimen. This increased 2-year survival of unresected GBM patients from 4.6% to 10.4 % (Stupp et al., 2009). Lately, due to the still-low survival rate, biopsy-only patients are often excluded from GBM clinical trials. It is known that hypoxic tumors are resistant to radiation therapy (Sheehan et al., 2010). Thus, Diffusion Pharmaceuticals Inc. added trans sodium crocetinate (TSC) to temozolomide-radiation

SUBMITTER: Gainer J 

PROVIDER: S-EPMC6216489 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature